How It Started
Johnson & Johnson was established in 1886, a time when surgical infection was still a major killer. The founding story reflects a direct response to a critical healthcare problem. Robert had visited the 1876 World’s Fair in Philadelphia, where he attended a talk by Dr. Joseph Lister on his new approach to surgery that involved sterilization of tools and antiseptic dressings. Rather than relying on Lister’s impractical sterilization method, because Lister’s recommended method for sterilization – spraying the operating room with carbolic acid – was found to be impractical and cumbersome, Johnson & Johnson found a ready market for its product.
The solution came in the form of ready-to-use sterile surgical dressings in 1886. They founded Johnson & Johnson in 1886 with 14 employees – eight women and six men. The target audience was hospitals and medical professionals desperate to prevent post-operative infections. The percentage of deaths due to infections following surgery was quite high, and hospitals were eager to find a solution.
Competitive Advantage
Johnson & Johnson built several key competitive advantages over time:
- Innovation and Research: The company established early leadership through continuous product innovation, from sterilization techniques to diversified medical solutions. Since the 1980s, Johnson & Johnson has continued to grow in most areas of medical research and development. Just a few of the company’s inventions include the first disposable contact lens, mainstream drug treatments for depression and schizophrenia, drug treatments for HIV/AIDS, and the first coronary stent.
- Strategic Acquisitions: In 1959, J&J acquired McNeil Laboratories in the US and also Cilag Chemie AG in Europe. These two acquisitions enabled the company to gain a significant presence in the field of pharmaceutical medicines for the first time. Later acquisitions further expanded its pharmaceutical and medical device portfolios significantly.
- Decentralized Structure: The company’s business is divided into two segments: Innovative Medicine and MedTech. This structure allows for specialised focus while maintaining operational efficiency.
- Brand Trust and Reputation: Johnson & Johnson is one of the world’s most valuable companies and is one of only two US-based companies that holds a prime credit rating of AAA.
Marketing Techniques
Johnson & Johnson employed diverse marketing strategies across its history:
- Multilingual Advertising: Shortly after the company was founded in 1886, Johnson & Johnson began creating advertising in multiple languages to better reach doctors, surgeons, employees, and the public. These ads were translated into 15 languages in the early 1900s.
- Professional and Consumer Targeting: The company maintained dual messaging strategies, targeting both healthcare professionals and consumers through specialized channels and publications.
- Educational Content: The company produced its first two products: a mainstream manual on treating injuries and the first mass-market first-aid kit. This educational approach helped establish brand authority.
- Brand Heritage Marketing: Johnson & Johnson does not rely on a single catchy advertising jingle for its corporate brand, but rather on a phrase that embodies its post-spin-off purpose and its historical commitment to the Credo: “Profoundly impact health for humanity.” This represents a shift from its consumer-focused past and reflects the company’s exclusive focus on being a global healthcare innovation leader.
How Johnson & Johnson Makes Money
The answer lies in a relentless focus on its two powerhouse divisions – Innovative Medicine and MedTech – which is why the company raised its full-year 2025 sales guidance to a range of $93.5 billion to $93.9 billion. The Innovative Medicine segment alone generated over 64% of 2023 revenue. This segment includes pharmaceuticals treating cancer, diabetes, HIV, and other conditions. The MedTech segment comprises surgical instruments, diagnostic devices, and orthopaedic products. The Consumer Healthcare division was spun off as a separate company, allowing J&J to focus exclusively on high-margin innovative healthcare solutions.
Market Share
The following table presents Johnson & Johnson’s market positioning:
| Metric | Details |
|---|---|
| Global Ranking | 2nd largest pharma company by market capitalisation globally |
| Forbes Global 2000 (2025) | Ranked 42nd globally |
| Fortune 500 (2025) | Ranked 48th among US corporations |
| Workforce | Approximately 138,000 employees globally |
| 2025 Sales Guidance | $93.5 billion to $93.9 billion |
| Innovative Medicine Segment | Over 64% of total revenue |
| Subsidiary Companies | Approximately 265 individual companies |
Business Model Canvas of Johnson & Johnson
Key Partners: Research institutions, healthcare providers, regulatory agencies, and medical device manufacturers. The company leverages partnerships through subsidiaries such as Janssen Pharmaceuticals and through strategic acquisitions.
Key Activities: Pharmaceutical research and development, medical device manufacturing, clinical trials, and regulatory compliance. The company operates an innovation ecosystem through Johnson & Johnson Innovation (JJI), which provides infrastructure and capital to support emerging healthcare technologies.
Value Proposition: Good health is the foundation of vibrant lives, thriving communities, and forward progress. For 140 years, the company has aimed to keep people well at every age and every stage of life. The focus remains on innovative medicines and advanced medical technologies that address critical healthcare needs.
Customer Segments: Hospitals and healthcare systems, physicians, patients requiring pharmaceutical treatments, and medical professionals utilising advanced medical devices. The company serves diverse market segments across developed and emerging economies.
Revenue Streams: Pharmaceutical sales (branded drugs and biologics), medical device sales, diagnostic products, and licensing agreements. High-margin innovative medicines drive the majority of revenue growth.
Key Resources: Extensive R&D capabilities, manufacturing facilities, an intellectual property portfolio including numerous patents, brand equity, and a global distribution network. The company has a global workforce of approximately 138,000 employees, led by its current Chairman and Chief Executive Officer, Joaquin Duato.
Channels: Direct sales to healthcare institutions, distribution partnerships, pharmaceutical wholesalers, pharmacy networks, and digital health platforms for patient engagement.
Cost Structure: Significant investment in R&D — typically 15–20% of revenue for pharmaceutical companies – alongside manufacturing and supply chain operations, regulatory compliance, clinical trials, and marketing to healthcare professionals.
Conclusion: Is It a Viable Business?
Johnson & Johnson represents one of the most viable and resilient healthcare businesses in the world. The company’s nearly 140-year operational history demonstrates exceptional sustainability and adaptability. A company nearly 140 years old, Johnson & Johnson continues to stay at the forefront of global healthcare – especially after spinning off its Consumer Health segment – through a relentless focus on its two powerhouse divisions: Innovative Medicine and MedTech.
The business model is robust because it concentrates on high-margin innovative pharmaceuticals and medical devices – sectors with strong demand drivers including ageing populations, chronic disease prevalence, and advancing technology adoption. The Innovative Medicine segment alone generated over 64% of 2023 revenue, driving the forecasted adjusted Earnings Per Share (EPS) to a tight range of $10.80 to $10.90 for the year. The company’s AAA credit rating underscores its financial strength, while its decentralised structure enables rapid innovation and market responsiveness. Despite historical controversies, J&J continues to invest heavily in research and maintains a diversified portfolio across therapeutic areas, positioning it as a sustainably viable business for decades to come.
Read The Business model of mastercard
Hi Friends, This is Swapnil; I love reading and sharing knowledge. Currently working as a content writer at startupsunion.com. You all can hang out with me here.